Prostate cancer — all decisions

The Board remands the issue of entitlement to service connection for prostate cancer due to a pre-decisional duty-to-assist error, specifically the failure to obtain an adequate dose estimate.

The Board granted an effective date of August 17, 2022, for the award of service connection for type II diabetes mellitus and residuals of prostate cancer.

The Board denied service connection for a lumbar spine disorder and prostate cancer as the evidence did not support a finding that these conditions were incurred in or caused by the Veteran's active military service.

The Board granted service connection for prostate cancer on a presumptive basis and assigned a 70 percent rating for posttraumatic stress disorder (PTSD).

The Board remands the claims for service connection for diabetes mellitus, type II and prostate cancer to obtain additional evidence related to the Veteran's exposure to herbicide agents under the PACT Act.

The Board remands the service connection claims for a brain lesion, cervical spine disability, respiratory issues, residuals of prostate cancer, and GERD due to the need for additional development, including obtaining outstanding service records, verifying potential herbicide exposure, and providing VA examinations.

The Board granted service connection for bladder cancer and prostate cancer, as the Veteran was presumed to have been exposed to herbicide agents during his service near the Korean DMZ.

The Board remands the claims for service connection for bilateral ankle disability, bilateral knee disability, prostate cancer, and hypertension (HTN) as well as the claim for special monthly compensation based on aid and attendance/housebound due to a failure to provide notice of the Veteran's right to an AOJ hearing.

The Board granted service connection for prostate cancer, resolving all doubt in the Veteran's favor and finding it at least as likely as not that the condition was caused by an in-service injury or event.

The Veteran's service connection for prostate cancer and ED is granted, while his claim for a bilateral eye disorder is denied.

The Board denied an increased rating for prostate cancer and the reduction of the disability rating from 60 percent to 40 percent effective December 1, 2024.

The Board denied service connection for prostate cancer, finding that the evidence does not support a causal relationship between the Veteran's prostate cancer and his military service, including any potential exposure to Agent Orange.

The Board remands the claims for service connection for various disabilities, including skin disability, hypertension, depression as secondary to prostate cancer, ischemic heart disease and coronary artery disease, prostate cancer, diabetes mellitus type II, thoracic aorta disabilities, sexual dysfunction, prostatitis, and cardiomegaly, due to insufficient evidence.

The Veteran was granted an initial 100 percent rating for residuals of bladder cancer and prostate cancer from November 28, 2011 through September 4, 2012 and April 1, 2013 through February 27, 2014, and an effective date of November 28, 2011 for the award of eligibility for DEA benefits under 38 U.S.C. Chapter 35.

The Board remands the claim for service connection for prostate cancer to afford the Veteran a VA examination to determine its nature and etiology.

The Board denied the Veteran's claims for a higher disability rating and special monthly compensation, finding that his symptoms did not meet the criteria for a 70 percent or higher rating from February 16, 2019, and prior to February 15, 2022.

The Board remands the Veteran's claim for a compensable rating for residuals of prostate cancer, status post RALP, to obtain an adequate medical examination.

The Board dismissed the appeals for service connection for hearing loss, malignant growths of the genitourinary system (prostate cancer), and Parkinson's disease due to improper election of review options. The claim for sleep apnea was remanded for further development.

The Board denied higher ratings for diabetes mellitus and peripheral neuropathy, granted a 20% rating for left and right lower extremity peripheral neuropathy of the sciatic nerve, and granted a TDIU from April 21, 2021.

The Board denied service connection for malaria and prostate cancer, while remanding claims for a kidney disorder, sinusitis, respiratory disorders, eye/vision disorder, generalized anxiety disorder, and acquired psychiatric disorder.